EBEmanuele Boatta

Emanuele Boatta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emanuele Boatta has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Safety and technical efficacy of pre-operative embolization of head and neck paragangliomas: A 10-year mono-centric experience and systematic review

    by Pierre De Marini, Michel Greget, Emanuele Boatta, Christine Jahn, Iulian Enescu, Julien Garnon, Danoob Dalili, Roberto Luigi Cazzato, Afshin Gangi


  • Percutaneous hydrodissection for thermoprotection during cryoablation of periureteric and pyeloureteric junction renal cell carcinomas

    by Julia Weiss, Julien Garnon, Roberto Luigi Cazzato, Pierre Auloge, Jean Caudrelier, Danoob Dalili, Emanuele Boatta, Pierre De Marini, Guillaume Koch, Afshin Gangi

    Objective To report our experience of percutaneous image-guided cryoablation of renal tumors located within 10 mm of the pyeloureteric junction (PUJ) and/or ureter, with hydrodissection as a stand-alone thermoprotective technique. Materials and methods All patients who were offered combined hydrodissection and cryoablation of the PUJ/ureter to treat stage-1 renal cell carcinoma were retrospectively reviewed. Data regarding patients, lesions, and outcomes were collected. Results Twenty tumors in 20 patients (13 males:7 females) with a mean age of 74.4 ± 7.5 were included. Mean tumor size was 27.6 ± 6.4 mm. Nearby vulnerable structure(s) were identified as the ureter in 5/20 cases, the PUJ in 8/20 cases and both the PUJ and the ureter in the remaining 7/20 cases (35%) cases. Mean minimal distance between the tumor and the vulnerable organ(s) was 4.8 ± 2.6 mm (range 0–10). A mean of 1.7 ± 0.6 spinal needles were used per intervention with a mean time to complete hydrodissection of 18.6 ± 13.4 min. Primary and secondary technical efficacy rates were 90% and 95%, respectively. Mean follow-up was 23.1 ± 9.2 months. There were no immediate or delayed complications, in particular no urothelial strictures. Two tumor recurrences occurred during follow-up, with a time to disease progression of 13 and 31 months, respectively. Conclusion hydrodissection of the PUJ/ureter to prevent thermal injury during cryoablation is an effective technique and does not seem to compromise the efficacy of ablation at short or mid-term follow-up.


  • Stomach Displacement Utilizing Levering of Blunt-Tip Needles

    by Julien Garnon, Roberto Luigi Cazzato, Pierre Auloge, Pierre De Marini, Julia Weiss, Danoob Dalili, Emanuele Boatta, Guillaume Koch, Afshin Gangi


  • Percutaneous MR-Guided Cryoablation of Low-Flow Vascular Malformation: Technical Feasibility, Safety and Clinical Efficacy

    by Pierre-Alexis Autrusseau, Roberto Luigi Cazzato, Pierre De Marini, Danoob Dalili, Guillaume Koch, Emanuele Boatta, Pierre Auloge, Julien Garnon, Afshin Gangi

    Purpose To retrospectively assess the technical feasibility, safety and clinical efficacy of percutaneous MR-guided cryoablation of low-flow vascular malformations (LFVM). Materials and Methods Between July 2013 and May 2019, 9 consecutive patients (5 male; 4 female; mean age 39.4 ± 15.3 years, range 15–68) underwent MR-guided cryoablation of LFVM. Patients were treated due to pain in all cases. Procedural data, complications and clinical results were analyzed. Results Technical success defined as complete coverage of the LFVM by the iceball without involvement of nearby non-target thermal-sensitive structures was achieved in 9/9 (100%) cases. Mean procedure time was 122 ± 20 min (range 90–150); 2–6 cryoprobes (mean 3.7 ± 1.2) and 2–4 freezing cycles (mean freezing time 19.8 ± 11.8 min; range 4–40) were applied. No complications were noted. Mean time from the first treatment to the last follow-up was 548 days (range 30–1776). Persistent/recurring pain was noted in 3/9 cases (33%) 30, 133 and 639 days after cryoablation, respectively, and was related in all cases to MR-confirmed local residual/recurring disease. A second cryoablation treatment was performed in these 3 cases with complete pain control at the last available follow-up (153, 25, 91 days, respectively). In the whole population, at mean 161 days (range 25–413) after the last treatment, on the numerical pain rate scale, pain significantly dropped from mean 6.4 ± 2.1 (range 3–9/10) before CA to mean 0.3 ± 0.9 (range 0–3/10) after (p = 0.009). Conclusions Percutaneous MR-guided cryoablation is technically feasible, safe and effective for the treatment of symptomatic LFVM. Level of Evidence Level 3b, retrospective cohort study.